Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for Obesity in PLWH on Dolutegravir-based ART
NCT06438146Phase 4Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- May 2024
- Primary completion
- May 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of liraglutide in obesity, sponsored by Brigham and Women's Hospital. Primary endpoints: Proportion of participants who screen and enroll among those approached, Time to reach study enrollment target and 3 more. Started May 2024; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06438146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06438146.